Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Relmada Therapeutics, Inc. (RLMD) Market Cap & Valuation Ratios

Relmada Therapeutics, Inc. (RLMD) has a market cap of $348.8M, with earnings according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

RLMDRelmada Therapeutics, Inc.Follow RLMD — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
348.8M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
5 Nov, in 12 days

Peers

biotechnology · nearest by market cap · trailing 12 months
CompanyMkt cap, $BP/EEV/SalesEV/EBITDAFCF yieldRev. growthOp. marginROIC
RLMD0.3———-13.2%——-62%
CCCC0.4—8.5——+2%-319%-84%
AVTX0.4————-87%—-43%
MPLT0.4——————-88%
EDIT0.4—4.5——+21%-161%—
FENC0.4—5.3——+78%-2%-94%
CAPR0.3——————-88%
ENTA0.3—2.3—-10.9%+0.7%-90%-115%
KYTX0.3——————-110%
AVIR0.3—0.3————-91%
ZURA0.3———————
Median of these 10—4.5—-10.9%+2%-126%-89%

.

Growth vs. price

each dot a company · hover or tap for values

Relmada Therapeutics, Inc. — questions

What is Relmada Therapeutics, Inc.'s market cap?
$348.8M.

Every figure on this page comes from Relmada Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.